Business
Anika Reports First Quarter 2025 Financial Results
First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solut
About this update from Anika Therapeutics Inc.
[{"type":"image","alt":"Anika Therapeutics Inc.","displaySize":"","headline":null,"caption":"Anika Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/87f8d0b1520f9e5cf005c5f7008d1e8b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hCNw0eG2QbR25b1UHhgLww--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/87f8d0b1520f9e5cf005c5f7008d1e8b","width":300,"height":157}},"lazy":false},{"type":"text","content":"First Quarter 2025 Commercial Channel revenue up 18%","length":52,"tagName":"p"},{"type":"text","content":"Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025","length":107,"tagName":"p"},{"type":"text","content":"Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity","length":86,"tagName":"p"},{"type":"text","content":"Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance","length":78,"tagName":"p"},{"type":"text","content":"BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for the first quarter ended March 31, 2025.","length":305,"tagName":"p"},{"type":"text","content":"First Quarter 2025 ResultsAnika announced first quarter revenue from continuing operations of $26.2 million, a 10% decrease compared to the same period in 2024. Commercial Channel revenue was strong, up 18% driven by continued growth of Integrity and international OA Pain Management. OEM Channel revenue, which includes U.S. OA Pain Management, was down 23% in the quarter, due to lower pricing for Monovisc® and Orthovisc®, sold by its commercial partner, J&J MedTech. During the quarter, Anika also achieved significant milestones for two key pipeline programs; filing the second Hyalofast PMA module and receiving formal written feedback from the previously reported FDA Type C meeting regarding Cingal, clearing the path to NDA filing.","length":745,"tagName":"p"},{"type":"text","content":"Cheryl Blanchard, President and CEO of Anika Therapeutics, commented: "Since our strategic realignment we have outperforme...